Oral composition for improving female skin state and application thereof

Abstract

The invention discloses an oral composition for improving female skin state and application thereof, the oral composition comprises ergothioneine and carob bean extract, the ergothioneine is used as a powerful endogenous antioxidant and provides direct oxidation defense for ovary and skin cells; and the carob bean extract accurately adjusts insulin sensitivity and hormone balance of the ovary through a core component DCI of the carob bean extract. According to the invention, the ergothioneine with strong anti-oxidation effect is combined with the carob bean extract which is good at metabolic regulation for the first time, and the combined product acts on the ovary-skin axis through the dual-channel synergistic effect of'anti-oxidation defense 'and'endocrine regulation'. Experiments show that the composition can synergistically improve estrogen secretion of ovarian granular cells and further promote skin collagen synthesis from inside to outside so as to shrink pores and inhibit melanin generation to brighten skin color, and the effect of the composition is remarkably superior to that of a single component.

Description

Technical Field

[0001] This invention belongs to the field of women's health and beauty technology, specifically relating to an oral composition for improving women's skin condition and its application. Background Technology

[0002] Skin condition, such as dullness, yellowing (requiring brightening and yellowing removal), and enlarged pores, is an important external indicator of a woman's health and beauty. Traditional solutions often rely on external care, such as salicylic acid to tighten pores and niacinamide to inhibit melanin. These methods offer only superficial relief, addressing the symptoms but not the root cause of the problem. In recent years, the concept of oral beauty supplements has gained increasing popularity. The academic and industrial communities have gradually recognized that the skin is an external "mirror" of internal metabolic health, and that oxidative stress and glycation are the core internal factors damaging skin cells, leading to collagen degradation and pigmentation disorders. Therefore, numerous oral products on the market are marketed with antioxidant (e.g., vitamin C, grape seed extract) or anti-glycation (e.g., aminoguanidine, certain plant flavonoids) as selling points.

[0003] However, existing oral treatments have significant drawbacks: most treat the skin as an independent target, with a "one-way" action mode, meaning the ingredients act directly on skin cells. This approach ignores the core internal organ that holds the "life and death" power over a woman's skin condition—the ovary. The ovary is the key organ for women to secrete estrogen, which is crucial for maintaining healthy skin. Estrogen promotes the synthesis of collagen and elastin by dermal fibroblasts, maintaining skin thickness and elasticity, thereby ensuring the stability of the structure around pores and visually shrinking them; it also regulates the function of melanocytes in the skin, reducing pigmentation and resulting in an even and radiant complexion.

[0004] In existing technologies, ergothioneine (EGT, a potent antioxidant) and carob extract (rich in DCI, an insulin sensitizer that helps improve polycystic ovary syndrome) have been proven to have positive auxiliary effects on female ovarian health. However, current research and patents only consider these two components in isolation. There is currently no inventive combination of ergothioneine and carob extract that uses "ovarian function maintenance" as a fundamental approach and the "ovarian-skin axis" systemic physiological pathway as a theoretical framework to achieve fundamental skin improvement from the inside out. Therefore, developing a synergistic and highly effective composition containing ergothioneine and carob extract is of great significance. Summary of the Invention

[0005] The purpose of this section is to outline some aspects of embodiments of the present invention and to briefly describe some preferred embodiments. Simplifications or omissions may be made in this section, as well as in the abstract and title of this application, to avoid obscuring the purpose of these documents; however, such simplifications or omissions should not be construed as limiting the scope of the invention.

[0006] In view of the problems existing in the above and / or prior art, the present invention is proposed.

[0007] Therefore, the object of the present invention is to overcome the shortcomings of the prior art and provide an oral composition for improving the condition of women's skin.

[0008] To solve the above-mentioned technical problems, the present invention provides the following technical solution: an oral composition for improving women's skin condition, characterized in that: the oral composition includes ergothioneine and carob extract, and the oral composition improves women's skin condition by regulating ovarian health.

[0009] As a preferred embodiment of the oral composition of the present invention, the content of D-chiroinositol in the carob extract is not less than 50%.

[0010] As a preferred embodiment of the oral composition of the present invention, wherein the weight ratio of ergothioneine to carob extract is 1:5 to 1:2770 by weight.

[0011] As a preferred embodiment of the oral composition of the present invention, wherein the weight ratio of ergothioneine to carob extract is 1:50 to 1:500 by weight.

[0012] As a preferred embodiment of the oral composition of the present invention, the improvement of female skin condition includes: increasing skin collagen content to shrink pores, and / or inhibiting melanin production to brighten skin tone.

[0013] As a preferred embodiment of the oral composition of the present invention, the oral composition is configured to synergistically enhance the estrogen secretion level of ovarian granulosa cells.

[0014] As a preferred embodiment of the oral composition of the present invention, the dosage form of the oral composition is tablets, capsules, soft capsules, powders, oral liquids or gummies.

[0015] As a preferred embodiment of the oral composition of the present invention, it further comprises one or more food-grade excipients selected from fillers, disintegrants, lubricants, flavoring agents, preservatives, or coating materials.

[0016] As a preferred embodiment of the oral composition of the present invention, it further comprises one or more synergistic nutrients selected from one or more of vitamin C, vitamin E, nicotinamide, selenium, zinc, collagen peptides, soy isoflavones, sodium hyaluronate, or grape seed extract.

[0017] Another object of the present invention is to overcome the shortcomings of the prior art and provide an oral composition for use in the preparation of a food or dietary supplement that improves the skin condition of healthy women by regulating the ovarian-skin axis, characterized in that: the improvement of skin condition includes shrinking pores and / or brightening skin tone.

[0018] Beneficial effects of this invention: This invention utilizes carob extract (DCI) as a "metabolic regulator" to improve ovarian insulin sensitivity, fundamentally optimizing the hormone secretion microenvironment. Simultaneously, it employs ergothioneine (EGT) as an "oxidative defense shield," effectively protecting ovarian cells from oxidative stress damage. These two components work synergistically to create a dual "metabolic-oxidative" protection for ovarian health, reshaping a healthy ovarian internal environment. A healthy ovary then stably secretes estrogen, instructing the synthesis of large amounts of dermal collagen through endocrine pathways, enhancing skin elasticity and support, thereby effectively shrinking pores; and regulating pigment metabolism, inhibiting abnormal melanin production at its source, achieving a brighter, less yellow complexion.

[0019] Experiments have shown that in the Transwell co-culture system simulating the "ovarian-skin axis," the optimal inflection points of the three core indicators representing ovarian function (estrogen levels), skin structure (collagen), and skin appearance (melanin) all occurred within the range of 1:50 to 1:500 for the ratio of ergothioneine to carob extract, demonstrating the existence of a clear "optimal synergistic window." Under all tested ratios, the combined effects were superior to the theoretical summation, broadly confirming the existence of a synergistic effect from a biological perspective. Attached Figure Description

[0020] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort. Wherein: Figure 1 This is a trend graph showing the content of ergothioneine prepared in Example 1.

[0021] Figure 2 This is a photograph of the oral composition used in Example 1.

[0022] Figure 3ABTS of ergothioneine and carob extract in Experimental Example 9 + Free radical scavenging rate trend chart.

[0023] Figure 4 The free radical scavenging rate and AGEs of the oral compositions in Examples 1-8.

[0024] Figure 5 The levels of collagen, melanin, and estrogen in the oral compositions of Examples 1-8 and Comparative Examples 1-3 are given.

[0025] Figure 6 The compressed candy prepared in Example 12.

[0026] Figure 7 The image shows the hardness test results of the compressed candy in Experiment Example 12. Detailed Implementation

[0027] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the specific embodiments of the present invention will be described in detail below with reference to the examples in the specification.

[0028] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein, and those skilled in the art can make similar extensions without departing from the spirit of the invention. Therefore, the invention is not limited to the specific embodiments disclosed below.

[0029] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The phrase "in one embodiment" appearing in different places in this specification does not necessarily refer to the same embodiment, nor is it a single or selective embodiment that is mutually exclusive with other embodiments.

[0030] The ergothioneine and carob extract in this invention are calculated based on 100% active ingredients.

[0031] Raw materials used in the embodiments of this invention: Ergotsulfur is produced through self-developed fermentation (see Example 1 for details) and has a purity of 99.9%. Carob extract was purchased from Shandong Aimeike Biotechnology Co., Ltd., with a DCI content of 95%. Sorbitol and maltitol were purchased from Shandong Bailong Chuangyuan Biotechnology Co., Ltd., with a content of ≥99.8%. Magnesium stearate was purchased from Shandong Guante Bioengineering Co., Ltd., with a content ≥99.0%; Vitamin C was purchased from CSPC Vitamin C Pharmaceutical (Shijiazhuang) Co., Ltd., with a vitamin C content of ≥99.0%. Formic acid and methanol: Shanghai Maclean Biochemical Technology Co., Ltd. Potassium persulfate, ABTS, anhydrous ethanol, phosphate buffer granules (pH=7.4), bovine serum albumin (BSA), glucose, dihydrotestosterone (DTH), sodium hydroxide (NaOH): Sinopharm Chemical Reagent Co., Ltd. Transwell chamber: Corning Incorporated; Trypsin: MedChemExpress LLC; SirCol collagen assay kit: Biocolor Limited; ELISA kit, human dermal fibroblasts, ovarian granulosa cells: Nanjing Senbeijia Biotechnology Co., Ltd. Human epidermal melanocytes: Shanghai Zhongqiao Xinzhou Biotechnology Co., Ltd.

[0032] Instruments used in the embodiments of this invention: Constant temperature and humidity incubator: Shanghai Boxun Medical Bio-Instrument Co., Ltd., BXS-400S; Freeze dryer: CHRIST, Germany, Alpha1-4LD plus; High performance liquid chromatograph: Shimadzu Corporation, Japan, LC-20AB; Physical property analyzer: Stable Micro Systems, UK, TA-XT plus; Autoclave: Shanghai Boxun Medical Bio-Instrument Co., Ltd., YXQ-50A; Microplate reader: Thermo Fisher Scientific China, Multiskan FC; Fluorescence spectrophotometer: Hitachi High-Tech Co., Ltd., F-7100.

[0033] Example 1 This embodiment provides an oral composition, specifically: (1) Preparation of high-purity ergothioneine: The strain was cultured by liquid fermentation under the following conditions: 25-28℃, pH 5.5-6.6, fermentation for 10 days, and mycelium was collected. After the mycelium was homogenized and broken by high pressure, it was extracted with hot water at 65-75℃ for 1-2 hours. The extract was purified by macroporous adsorption resin chromatography, and ergothioneine was collected, eluted, and concentrated. The concentrate was subjected to crystallization and recrystallization steps, and finally freeze-dried under vacuum to obtain ergothioneine with a purity of not less than 99%.

[0034] Ergothioneine purity determination: Ergothioneine content was determined by high performance liquid chromatography (HPLC). Detection conditions: XDB-C18 column (250 cm × 4.6 mm, 5 μm), mobile phase: 0.1% formic acid aqueous solution: methanol = 9:1 (V:V), flow rate: 0.7 mL / min, injection volume: 20 μL, column temperature: 25℃, detection wavelength: 254 nm.

[0035] Preparation of the standard curve: Ergothioneine concentration (mg / L) was plotted on the x-axis, and peak area (μAU·s×10⁻¹⁰) was plotted on the y-axis. 5 Using y as the ordinate, a standard curve for ergothioneine was plotted, yielding the standard regression equation for ergothioneine: y = 2.5859x + 103.35. Figure 1 As shown, R 2 =0.9943, where y is the peak area and x is the ergothioneine concentration.

[0036] The final calculated concentration of the self-made ergothioneine was 99.4% ± 0.02%.

[0037] (2) Weigh 1 part ergothioneine, add 5 parts carob extract, mix well to obtain the oral composition, such as Figure 2 As shown.

[0038] The difference between Examples 2-8, Comparative Examples 1-3 and Example 1 lies in the different ratios of ergothioneine and carob extract, as shown in Table 1.

[0039] Table 1. Proportions of different embodiments

[0040] Example 9 This embodiment investigates the free radical scavenging rate of the ergothioneine and carob extract composition in the above embodiments, specifically: ABTS + Free radical scavenging rate determination: Since both ergothioneine and carob extract have good water solubility, ABTS was chosen as the assay material for free radical scavenging rate determination. + As the experimental substrate material.

[0041] Take 200.0 mg of ABTS, add 34.4 mg of potassium persulfate, and dilute to 50 mL with ultrapure water. Shake well and incubate at room temperature in the dark for 24 h to prepare ABTS stock solution. Dilute with 95% ethanol to prepare a working solution with an absorbance of (0.70 ± 0.02) at 734 nm. Add 20 μL of sample to a 96-well plate, then add 180 μL of working solution. Incubate at room temperature in the dark for 6 min, and record the absorbance at 734 nm using a microplate reader. Calculate the ABTS content of the sample according to the formula. + Free radical scavenging rate.

[0042] ABTS + Free radical scavenging rate = In the formula, A s A represents the absorbance of the mixture of sample and ABTS solution. c A represents the absorbance of the sample and ultrapure water mixture. bA represents the absorbance of a mixture of ultrapure water and ABTS solution. o The absorbance of ultrapure water.

[0043] The effective mass concentration required to achieve a 50% clearance rate is defined as IC50. 50 Value. IC 50 The smaller the value, the stronger the free radical scavenging ability of the sample.

[0044] Then, ABTS with different antioxidants + The free radical scavenging ability was compared with the theoretical group, and the synergistic index (q value) was calculated according to the King's formula.

[0045] q= In the formula, A represents the antioxidant capacity measured after mixing ergothioneine and a single antioxidant, B represents the antioxidant capacity of ergothioneine in the mixture, and C represents the antioxidant capacity of carob extract in the mixture.

[0046] Table 2 ABTS of different samples + Free radical scavenging ability

[0047] As shown in Table 2, the IC50 of carob extract for free radical scavenging is... 50 The concentration was 27.7g, indicating that carob extract, or DCI, is not inherently a direct and potent antioxidant. The carob extract used in this invention contains over 95% DCI, meaning that the content of polyphenols and flavonoids, which may have non-specific antioxidant activity, is extremely low, resulting in a low final IC50 concentration. 50 High. ABTS + The free radical scavenging rate experiment is essentially a measurement of chemical reactions. The core function of DCI in the human body is as a second messenger in the insulin signaling pathway, responsible for regulating glucose metabolism and improving insulin sensitivity. This is a delicate cellular signaling regulation function, and its chemical structure is not well-suited to such rapid electron transfer reactions.

[0048] Table 3 ABTS of different samples + Free radical scavenging rate

[0049] As shown in Table 3, ergothioneine and carob extract in ABTS +The model exhibits dose-dependent antagonism. At low concentrations, carob extract has little effect on ergothioneine, with their free radical scavenging effects essentially additive. However, as the proportion of carob extract in the composition increases, its inhibitory effect on the antioxidant activity of ergothioneine becomes stronger, leading to a strong antagonistic effect. This indicates the presence of a component in carob extract that, while itself having low antioxidant activity, actively interferes with the antioxidant function of ergothioneine.

[0050] Example 10 This embodiment explores the superior anti-glycation properties of the ergothioneine and carob extract combination in the above embodiments, specifically: Bovine serum albumin (BSA)-glucose saccharification assay: Phosphate-buffered saline (PBS) preparation: Pour one packet of phosphate-buffered saline granules into 1 L of water, transfer it to a 1 L volumetric flask, bring the volume to a final volume, and sterilize it in an autoclave. At this point, the PBS concentration is 20 mmol / L and the pH is 7.4.

[0051] Preparation of BSA-glucose solution: Weigh 10 g of BSA and 90.08 g of glucose and dissolve them in 0.5 L of PBS to make the BSA concentration 20 g / L and the glucose concentration 1 mol / L. Dispense the BSA-glucose solution into 5 mL sealed, high-pressure, high-temperature resistant glass jars, 2.5 mL / tube.

[0052] Dissolve the sample in PBS solution, then add 2.5 mL to a glass tube, tighten the cap, heat in a 100°C water bath for 40 min, and immediately remove it after the reaction is complete and place it in an ice-water bath to cool before testing. Keep it at 4°C until testing is complete.

[0053] Fluorescent AGEs determination: Take 3 mL of sample solution diluted to an appropriate concentration and use an F-7100 fluorescence spectrophotometer to measure its fluorescence intensity at an excitation wavelength of 380 nm and an emission wavelength of 450 nm. The slit width for both excitation and emission wavelengths is 5 nm, the scanning speed is 1200 nm / min, and the voltage is 400 V.

[0054] Inhibition rate = In the formula, A s A represents the fluorescence intensity of the sample and the BSA-glucose solution mixture. o The fluorescence intensity is measured by a mixture of PBS solution and ultra-BSA-glucose solution.

[0055] Table 4. BSA-glucose inhibition capacity of different samples

[0056] DCI is the core active ingredient in carob extract, which can specifically and efficiently capture methylglyoxal, a highly toxic intermediate in the glycation process, thereby preventing the formation of advanced glycation end products (AGEs) at the source. Ergothioneine has extreme antioxidant capacity and cytoprotective effects, and can effectively scavenge various reactive oxygen species, fundamentally inhibiting oxidative stress-driven glycation reactions.

[0057] As shown in Table 4, in the BSA-glucose anti-glycation model, the carob extract in the composition of this invention exhibited significantly superior inhibitory activity compared to ergothioneine, and ergothioneine and carob extract showed a significant synergistic effect. More importantly, when ergothioneine and carob extract were combined in a specific ratio, the anti-glycation inhibition rate was significantly higher than the theoretical sum of values ​​in all test ratios (Examples 1-8), demonstrating a universal and powerful synergistic effect between the two.

[0058] This result reveals the unique mechanism of action of the composition of this invention: carob extract acts as the primary executor of anti-glycation, while ergothioneine acts as a highly efficient synergist. We infer that carob extract inhibits glycation at its source through its metabolic regulatory function, while ergothioneine scavenges glycation intermediates and protects proteins through its antioxidant function. Together, they constitute a highly efficient dual anti-glycation system through distinct but complementary pathways.

[0059] Example 11 This embodiment explores the superior effects of the ergothioneine and carob extract combination in the above embodiments on the ovarian-skin condition, specifically as follows: The Transwell co-culture system was used to verify that ovarian cells treated with the composition of this invention can remotely improve the condition of skin cells by secreting certain substances.

[0060] 1. Cell resuscitation and culture Choose a 3μm Transwell chamber.

[0061] 2. Transwell system PCB layout 2.1 Lower layer (skin cells) plaques: Skin cells (human skin fiber cells / human skin melanocytes) were digested and resuspended with trypsin. The skin cells were then seeded into the bottom wells of a Transwell plate (lower layer) and complete culture medium was added. The plate was placed in an incubator (37°C, 5% CO2) to allow the cells to adhere (usually overnight).

[0062] 2.2 Upper layer (ovarian cells) plating: The next day, ovarian granulosa cells were digested and resuspended. Ovarian cells were seeded into the Transwell insert (upper chamber), and the upper chamber, now seeded with ovarian cells, was carefully placed into the lower well plate, which had been lined with skin cells. At this point, the co-culture system was officially established. The upper and lower cells shared the culture medium but were physically separated.

[0063] 3. Modeling and Drug Administration 3.1 Synchronization: After the cells have adhered to the culture medium, replace the culture medium in the upper and lower chambers with serum-free or low-serum culture medium and culture for 12 hours to synchronize the cell cycle.

[0064] 3.2 Grouping and Processing (Key Steps): Replace with a new culture medium containing the drug and modeling agent. Note: The composition of the culture medium added to the upper and lower chambers is exactly the same at this time.

[0065] The groups are as follows: Blank control group: normal culture medium.

[0066] Model control group: Culture medium containing dihydrotestosterone (DTH).

[0067] Single-component group 1: Culture medium containing DTH + ergothioneine.

[0068] Single-component group 2: Culture medium containing DTH + carob extract.

[0069] This invention relates to a culture medium containing DTH, ergothioneine, and carob extract.

[0070] Return the culture plate to the incubator (incubator environment: 37℃, 5% CO2) and incubate for a total of 24-48 h.

[0071] 4. Sample collection and testing 4.1 Collect conditioned medium: After co-culture, carefully remove the upper chamber of the Transwell. Collect the culture medium from the lower chamber, which is a "conditioned medium" containing secretions from skin cells and ovarian cells. After centrifugation, the supernatant can be used to detect certain soluble factors.

[0072] Skin cells were collected: skin cells in the lower pores were digested with trypsin, resuspended, and counted for subsequent collagen or melanin quantification.

[0073] 4.2 Collection of ovarian cells: Ovarian cells in the upper chamber of the Transwell were digested for subsequent assays (such as detecting intracellular antioxidant enzyme activity or related gene expression).

[0074] 4.3 Core Efficacy Testing: Collagen content determination: The collected skin fibroblasts were quantitatively analyzed using the SirCol collagen detection kit.

[0075] Melanin content determination: The collected melanocytes were quantitatively analyzed using the NaOH lysis method.

[0076] Estrogen level measurement: Using an ELISA kit, the content of estradiol (E2) in the collected conditioned culture medium was detected, which directly proved the improvement of ovarian function.

[0077] Table 5. Effects of different samples on skin cells

[0078] As shown in Table 5, in the Transwell co-culture system simulating the "ovarian-skin axis", this invention found that the optimal turning points of the three core indicators representing ovarian function (estrogen level), skin structure (collagen) and skin appearance (melanin) all occurred within the range of ergothioneine to carob extract ratio of 1:50 to 1:500 (Examples 3-5).

[0079] This data provides irrefutable evidence that the compositions of this invention possess a clearly defined "optimal synergistic window" within biological systems. Within this window, the two major pathways of metabolic regulation and oxidative defense achieve a precise balance, thereby driving the ovarian-skin axis to perform at its peak function.

[0080] While deviations from this window may yield better results for some individual indicators, only within this optimal window can a comprehensive and synergistic improvement in ovarian and skin health, as well as structural and pigmentation issues, be achieved. This demonstrates that the invention is based on a profound understanding of complex physiological systems, resulting in rational design and precise regulation. Furthermore, in all tested ratios, the composition outperformed the theoretical summation, which broadly confirms the existence of a synergistic effect from a biological perspective.

[0081] Example 12 This embodiment illustrates the application of the ergothioneine and carob extract composition in actual production. Here, we choose to prepare it as a compressed candy as one of its practical applications.

[0082] Weigh out 1 part ergothioneine and 20 parts carob extract, mix them thoroughly, then add 10 parts sorbitol, 10 parts maltitol, 2 parts magnesium stearate, and 1 part vitamin C. Stir well and compress into tablets with a tablet weight of 0.8g, a compression speed of 200 r / min, and a pressure of 2 MPa. The final product is a uniformly colored compressed candy, as shown below. Figure 6 As shown.

[0083] The hardness of tablets containing ergothioneine and carob extract was determined using a physical property analyzer (TA-XT plus, Stable Micro Systems, UK).

[0084] The measurement procedure was as follows: P2 probe, test speed 5 mm / s, test distance 3 mm.

[0085] The results are as follows Figure 7 As shown, the final measured hardness was 8092.34g.

[0086] In this invention, carob extract (DCI) acts as a "metabolic regulator," improving ovarian insulin sensitivity and optimizing the hormone secretion microenvironment from the root. Ergothioneine (EGT) acts as an "oxidative defense shield," effectively protecting ovarian cells from oxidative stress damage. Together, they provide a dual "metabolic-oxidative" guarantee for ovarian health, reshaping a healthy ovarian internal environment. A healthy ovary then stably secretes estrogen, which, through the endocrine pathway, instructs the synthesis of large amounts of dermal collagen, enhancing skin elasticity and support, thereby effectively shrinking pores; and regulates pigment metabolism, inhibiting abnormal melanin production at its source, achieving a brighter, less yellow complexion.

[0087] This invention is the first to integrate two components along a novel pathway called the "ovarian-skin axis," and provides in vitro experimental evidence demonstrating that the composition synergistically improves ovarian cell function, and that the ovarian cell environment after intervention more effectively promotes skin health. This provides an oral composition with a unique mechanism, clearly defined target, and synergistic effects for addressing fundamental skin problems in women caused by internal endocrine imbalances.

[0088] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all such modifications or substitutions should be covered within the scope of the present invention.

Claims

1. An oral composition for improving the condition of women's skin, characterized in that: The oral composition comprises ergothioneine and carob extract, and the oral composition improves women's skin condition by regulating ovarian health.

2. The oral composition according to claim 1, characterized in that: The carob extract contains no less than 50% D-chiroinositol.

3. The oral composition according to claim 1, characterized in that: The weight ratio of ergothioneine to carob extract is 1:5 to 1:2770, based on parts by weight.

4. The oral composition according to claim 1, characterized in that: The weight ratio of ergothioneine to carob extract is 1:50 to 1:500, based on parts by weight.

5. The oral composition according to claim 1, characterized in that: The improvements to women's skin condition include: increasing skin collagen content to shrink pores, and / or inhibiting melanin production to brighten skin tone.

6. The oral composition according to claim 1, characterized in that: The oral composition is formulated to synergistically enhance estrogen secretion levels in ovarian granulosa cells.

7. The oral composition according to claim 1, characterized in that: The dosage form of the oral composition is tablets, capsules, soft capsules, powders, oral liquids, or gummies.

8. The oral composition according to claim 1, characterized in that: It also contains one or more food-grade excipients selected from fillers, disintegrants, lubricants, flavoring agents, preservatives, or coating materials.

9. The oral composition according to claim 1, characterized in that: It also contains one or more synergistic nutrients selected from one or more of vitamin C, vitamin E, niacinamide, selenium, zinc, collagen peptides, soy isoflavones, sodium hyaluronate, or grape seed extract.

10. The use of the oral composition according to any one of claims 1 to 9 in the preparation of a food or dietary supplement that improves the skin condition of healthy women by modulating the ovarian-skin axis, characterized in that: The improvements in skin condition include minimizing pores and / or brightening skin tone.

Images